Establishment and Characterization of Mammalian Cell Lines Stably Expressing Human L-Type Amino Acid Transporters

Emiko Morimoto¹, Yoshikatsu Kanai²,³, Do Kyung Kim¹,³, Arthit Chairoungdua¹, Hye Won Choi¹, Michael F. Wempe⁴, Naohiko Anzai¹, and Hitoshi Endou¹,⁵,*

¹Department of Pharmacology and Toxicology, Kyorin University School of Medicine, Tokyo 181-8611, Japan
²Department of Pharmacology, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
³Department of Oral Physiology, Chosun University College of Dentistry, Gwangju, Korea
⁴Department of Pharmacology, James H. Quillen College of Medicine, East Tennessee State University, Johnson City, TN 37614-1708, USA
⁵J-Pharma Co., Ltd., Tokyo 160-0022, Japan

Received September 1, 2008; Accepted October 27, 2008

Abstract. System L (SL), a basolateral amino acid transporter, transports large neutral amino acids (LNAAs) in a Na⁺-independent manner. Previously, we identified two isoforms of transporters: L-type amino acid transporter 1 (LAT1) and 2 (LAT2) and revealed their distinct substrate selectivity and transport properties. In this study, to establish more stable human LAT1 (hLAT1) and LAT2 (hLAT2) in vitro assay systems, we established mouse cell lines stably expressing hLAT1 (S2-LAT1) and hLAT2 (S2-LAT2). Real-time quantitative RT-PCR analysis revealed that S2-LAT1 and S2-LAT2 cells express hLAT1 and hLAT2 mRNAs at 20 – 1000-fold higher levels than those of endogenous mouse Lat1 and Lat2. S2-LAT1 and S2-LAT2 mediated [¹⁴C]L-leucine transport properties were measured and corresponded to results observed via Xenopus oocytes. Using these cells, the data demonstrate that hLAT1 and hLAT2 exhibit different characters in the acceptance of α-methyl amino acids and amino acid–related compounds with bulky side chains such as thyroid hormones and melphalan. S2-LAT1 and S2-LAT2 cells are expected to facilitate hLAT1 and hLAT2 substrate recognition research and contribute to drug development by providing an efficient assay system to screen for chemical compounds that interact with hLAT1 and hLAT2.

Keywords: amino acid transporter, system L (SL), SLC7, L-type amino acid transporter (LAT) 1, LAT2

Introduction

System L (SL), a basolateral amino acid transporter, transports large neutral amino acids (LNAAs) in a Na⁺-independent manner (1, 2). SL plays a pivotal role in amino acid (AA) absorption via the small intestine and renal proximal epithelial cells (1). SL has been shown to support cell growth and proliferation in both normal and tumor cells (1, 3, 4). Furthermore, AA penetration through the blood-brain barrier (BBB) and placenta barrier (PB) utilize SL transporters (1). SL accepts many substrates including naturally occurring AA and AA-related compounds such as L-dopa, a therapeutic drug for Parkinsonism; melphalan, an anti-cancer phenylalanine mustard; thyroid hormones, triiodothyronine (T3) and thyroxine (T4); gabapentin, an anti-convulsant drug; and S-(1,2-dichlorovinyl)-L-cysteine, a neurotoxic cysteine conjugate (1, 5 – 10). Due to the various levels of endogenous SL activity present in cultured cells and tissue preparations, methodical compound SL interactions have thus far been limited. Therefore, in vitro models expressing specific SL transporters are required.

Using cDNA cloning, four SL transporter isoforms designated as L-type AA transporter 1 (LAT1), 2 (LAT2), 3 (LAT3), and 4 (LAT4) have been identified (11 – 14). Among these isoforms, LAT1 and LAT2 are
predicted as 12-transmembrane proteins belonging to the hetero-dimeric AA transporter SLC7 family (3, 11, 12, 15–20). Required for functional expression in the plasma membrane, LAT1 and LAT2 require an additional single membrane spanning protein known as the 4F2 cell surface antigen heavy chain (4F2hc) (11, 12). LAT1 mediates Na\(^+\)-independent AA exchange and prefers LNAA substrates with bulky or branched side chains (11). Highly expressed in tumor cells, LAT1 supports growth by transporting AA (4, 21, 22). Present at the BBB and the PB, LAT1 likely contributes to the permeation of AAs and AA-related drugs through blood-tissue barriers (23–26). In contrast, LAT2 not only transports LNAA but also transports small neutral AAs. LAT2 is expressed more ubiquitously than LAT1 (12, 27, 28); LAT2 is highly expressed in the basolateral membrane of the small intestine and kidney epithelial cells (28).

LAT1 and LAT2 functional properties have been examined using the expressed *Xenopus laevis* oocyte model. However, a more ideal in vitro model to screen function and regulation requires mammalian cell systems; establishing mammalian culture models may afford a more robust in vitro model (i.e., high throughput screening tools) over the oocyte model. Therefore, the present study describes our efforts to establish and characterize mouse cell lines stably expressing human LAT1 (hLAT1) and human LAT2 (hLAT2). We illustrate the following in this study: 1) that exogenously introduced hLAT1 and hLAT2 become expressed at fairly high levels and dominate over endogenous mouse LAT1 and LAT2, and 2) that the transport function of these stably transfected mammalian cell lines reflect the properties of exogenously introduced hLAT1 and hLAT2.

**Materials and Methods**

*Materials*

\[^{[14]}\text{C}\]*-Leucine was purchased from Du Pont NEN. Gabapentin and droxidopa were provided by Parke-Davis Pharmaceutical Research (Ann Arbor, MI) and Sumitomo Pharmaceutical Co., Ltd. (Osaka), respectively. Unless specifically indicated, the remaining compounds and reagents were purchased from Sigma-Aldrich Chemical Company (St. Louis, MO, USA). The chemical structures of AA-related drugs used in the present investigation are presented in Fig. 1.

*Establishment of S2-LAT1 and S2-LAT2 cell lines*

S2 cells were derived from transgenic mice harboring the temperature-sensitive simian virus 40 large T-antigen gene and cultured in RITC 80-7 medium (IWAKI, Tokyo) containing 5% FBS, 10 \(\mu\)g/ml transferrin, 0.08 U/ml insulin, and 10 ng/ml recombinant EGF (29). Cells were subcultured in a medium

---

**Fig. 1.** Chemical structures of amino acid–related drugs used in the present study.
containing 0.05% trypsin–EDTA solution and used at passage 60–100 (29, 30). The full-length cDNAs for human L-type AA transporter 1 (hLAT1) (GenBank /EMBL/DDBJ accession no. AB018009) (4), and human L-type AA transporter 2 (hLAT2) (GenBank /EMBL/DDBJ accession no. AB037669) (27) were subcloned into pcDNA3.1; a mammalian expression vector (Invitrogen, San Diego, CA, USA) at KpnI/EcoRV and NotI restriction enzyme cleavage sites to obtain plasmids designated pcDNA3.1-hLAT1 and pcDNA3.1-hLAT2, respectively. The pcDNA3.1-hLAT1, pcDNA3.1-hLAT2, and pcDNA3.1 plasmid vector without insert were cotransfected with pSV2neo, a neomycin-resistance gene, into S2 cells using LIPOFECTAMIN 2000 regent (Invitrogen) according to the manufacturer’s instructions (30). At 48 h after transfection, cells were subcultured in medium containing 400 μg/ml geneticin. The cell clones were isolated using a cloning cylinder (30). We obtained 17 colonies of S2-LAT1 and 21 colonies of S2-LAT2 cells and then we picked 11 and 12 colonies based on the RT-PCR experiment, respectively. Finally, we selected final clones that showed highest transport activities of \( [{^1}\text{C}]\text{leucine} \). The cell clones transfected with pcDNA3.1 plasmid vector without insert were named S2-mock.

Reverse transcription polymerase chain reaction (RT-PCR)
Degenerate PCR primers were designed based on the AA sequences of hLAT1 (GenBank/EMBL/DDBJ accession no. AB018009), hLAT2 (GenBank/EMBL/DDBJ accession no. AB037669), mouse Lat1 (mLat1) (GenBank/EMBL/DDBJ accession number AB023409), mouse Lat2 (mLat2) (GenBank/EMBL/DDBJ accession number AF171668), and mouse 4F2hc (m4F2hc) (GenBank/EMBL/DDBJ accession number AB023408). The primers used in this experiment are indicated in Table 1. A 1-μg sample of total RNA prepared from S2-LAT1, S2-LAT2, and S2-mock cell lines using RNA purification kit ISOGEN (NIPPONGENE, Tokyo) was reverse-transcribed and used as a template for subsequent PCR with the set of degenerate primers (31). PCR was performed according to the following protocol: 94°C (30 s), 60°C (30 s), 72°C (60 s); 35 cycles. PCR products were subcloned in pCR II-TOPO vector using a TA cloning kit (Invitrogen) and sequenced by the dye terminator cycle sequencing method (Applied Biosystems, Foster City, CA, USA) (12).

Real-time quantitative RT-PCR
The 7700 Sequence Detector System (Applied Biosystems) was used for Real-time quantitative RT-PCR (32, 33). Briefly, each RT-PCR reaction mixture (50 μl) included 250 ng of total RNA, 25 μl of Taqman Universal PCR Master Mix (Applied Biosystems), 0.5 μl of forward and reverse primer (10 μM), and 1.0 μl of corresponding Taqman probe (5000 nM). RT-PCR cycle parameters were 50°C (2.0 min), 95°C (10.0 min), followed by 40 cycles at 95°C (15 s) and 60°C (60 s). The primers and probes were designed using Primer Express software (Applied Biosystems) and synthesized by Applied Biosystems. The sequences of primers used in this study are shown in Table 2. The concentrations of all primers and probes were optimized for LAT1; the concentrations of reverse and forward primers used for LAT1 were 900 nM. The LAT1 probe concentration was 250 nM.

Anti-peptide antibody generation
Oligopeptides [MAGAGPKRRALAAC] corresponding to AA residues 1–13 of hLAT1 and oligopeptides [EEANEDMEEQQQC] corresponding to AA residues 505–516 of hLAT2 were synthesized. The C-terminal cysteine residues were introduced for conjugation with keyhole limpet hemocyanine. Anti-peptide polyclonal antibodies were generated as described elsewhere (4).

<table>
<thead>
<tr>
<th>Protein</th>
<th>Direction</th>
<th>Sequence (5' to 3')</th>
<th>Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>hLAT1</td>
<td>Forward</td>
<td>GCATGCGCAGAGGCCAGTTAA</td>
<td>1617–1637</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>TATGTCAGGAGTCCATCGGG</td>
<td>2215–2235</td>
</tr>
<tr>
<td>hLAT2</td>
<td>Forward</td>
<td>TCCCCATCATACCTGCACCCA</td>
<td>2836–2856</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>TGCCCCAAGACAGCATGACAC</td>
<td>3527–3547</td>
</tr>
<tr>
<td>mLat1</td>
<td>Forward</td>
<td>GAGACCCTAGAGATGGAACCC</td>
<td>2154–2174</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>TCACATCACACTGGTGACAGAG</td>
<td>2569–2590</td>
</tr>
<tr>
<td>mLat2</td>
<td>Forward</td>
<td>GCCCATGGTGAGGTCAATGC</td>
<td>2028–2048</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>GGCTTGGCTCTGCAGTCTGA</td>
<td>2506–2526</td>
</tr>
<tr>
<td>m4F2hc</td>
<td>Forward</td>
<td>GAAGAACGGTCTGGTGAAGATC</td>
<td>194–215</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>CTGCAAGGCAGTCAGGACTCAGT</td>
<td>612–632</td>
</tr>
</tbody>
</table>
Antisera were affinity-purified as described elsewhere (4).

**Western blot analysis**

Cell membranes of S2-mock cells, S2-LAT1 cells, and S2-LAT2 cells as well as T24 human bladder carcinoma cells were prepared as described elsewhere (19), with minor modifications. Briefly, these cells were homogenized in 9 vol. of a solution containing 50 mM Tris-HCl (pH 7.5), 25 mM KCl, 1 mM MgCl$_2$, 1 mM phenylmethylsulfonyl fluoride, and 0.25 M sucrose, with 15 strokes in a Dounce homogenizer. The homogenate was centrifuged for 10 min at 8,000 × g, and the supernatant was centrifuged further for 1 h at 100,000 × g. After centrifugation, the membrane pellet was resuspended in a solution containing 0.25 M sucrose, 100 mM KCl, 5 mM MgCl$_2$, and 50 mM Tris (pH 7.4). The protein samples were heated at 100°C for 5 min in the sample buffer either in the presence (reducing condition) or absence (nonreducing condition) of 5% 2-mercaptoethanol and then subjected to SDS-PAGE. Western blot analysis was done as described above. The anti-hLAT1 antibody and the anti-hLAT2 antibody were used to detect hLAT1 and hLAT2, respectively. In the absorption experiments, the membranes were treated with primary antibodies in the presence of antigen peptides (100 μg/ml) (4).

**Immunoprecipitation**

S2-LAT1 and S2-LAT2 cells were lysed with a lysis buffer (1% Nonidet P-40, 50 mM Tris-Cl, pH 7.4, 0.15 M NaCl, 10 mM EDTA, PMSF, leupeptin, antipain, chymostatin trypsin inhibitor) and incubated with anti-mouse 4F2hc antibody (5 μl) (BD Bioscience, San Jose, CA, USA) and protein A-Sepharose 4B (Amersham Pharmacia Biotech) at 4°C for 2 h. The protein samples were electrophoresed in SDS-PAGE. Western blot analysis was done as described above. The anti-hLAT1 antibody and the anti-hLAT2 antibody were used to detect hLAT1 and hLAT2, respectively. In the absorption experiments, the membranes were treated with primary antibodies in the presence of antigen peptides (100 μg/ml) (4).

**Uptake measurement**

For AA uptake measurements, S2-LAT1, S2-LAT2, and S2-mock cells were used two days after plating (90% – 100% confluence) on 24-well plates (30). After removal of the medium, the cells were washed twice with Hank’s Na$^+$ free buffer (125 mM choline chloride, 4.8 mM KCl, 1.3 mM CaCl$_2$, 1.2 mM MgCl$_2$, 25.0 mM HEPES, and 5.0 mM Tris, pH 7.4) supplemented with D-glucose (5.6 mM) and preincubated for 10 min (37°C). Thereafter, cells were incubated (1.0 min, 37°C) with uptake medium (500 μl of Hank’s Na$^+$-free buffer) containing [^{14}C]-leucine. The cells were washed three times with medium and solubilized with 0.1 N NaOH (500 μl). Substrate accumulation was then measured by counting radioactivity by liquid scintillation counting (LSC; LSC6100, Aloka, Tokyo) (20, 34).

For the inhibition experiments, unless otherwise

---

**Table 2. Real-time RT-PCR primer sequences**

<table>
<thead>
<tr>
<th>Target</th>
<th>Forward</th>
<th>Reverse</th>
<th>TaqMan</th>
<th>TaqMan</th>
</tr>
</thead>
<tbody>
<tr>
<td>hLAT1</td>
<td>CCGCTGCACATGGGACAGA</td>
<td>GTCCCTTGACGAGTGGAAATT</td>
<td>6 FAM-AAGCCGGCTGCTCATAGGACCTGCATCC-TAMRA</td>
<td></td>
</tr>
<tr>
<td>hLAT2</td>
<td>GGTCTCTGATGCATGGCTCCTGTTG</td>
<td>GAGGGCCTTTTTTGAGGATCTCC</td>
<td>6 FAM-AAAGGTTAGTGCCAGCGCAGGCGC-TAMRA</td>
<td></td>
</tr>
<tr>
<td>mLat1</td>
<td>CACTCTGATGGTCACTTGTATAGTT</td>
<td>TCCATATGGAGCCAGCGACCATCTGAGTA</td>
<td>6 FAM-TCAGATGGTGCACTCGATGAC-TAMRA</td>
<td></td>
</tr>
<tr>
<td>mLat2</td>
<td>CCCAGCAATAGCTAGGAGAAGACA</td>
<td>GGAAGAAGGAAGCCACATCTGAGTA</td>
<td>6 FAM-TGTCAGGAGCGAGGAGGAG-GAGGA-TAMRA</td>
<td></td>
</tr>
<tr>
<td>m4F2hc</td>
<td>GAAGACGGTCTGGTGAAGATCA</td>
<td>TGGATAAGCAGGTGGAACTTGA</td>
<td>6 FAM-TGTCAGGAGCGAGGAGGAGGAGGA-TAMRA</td>
<td></td>
</tr>
</tbody>
</table>
indicated, [\(^{14}\text{C}\)]-leucine uptake (10 \(\mu\text{M}\)) by S2-LAT1, S2-LAT2, or S2-mock cells was measured in the presence or absence of 1.0 mM non-labeled test compounds. For T3, T4, and melphalan, the effects of non-radiolabeled compounds were examined on the uptake of 1.0 \(\mu\text{M}\) [\(^{14}\text{C}\)]-leucine in the uptake solution containing a final concentration of 1.0% DMSO (4).

The AA substrate \(K_m\) and \(V_{\text{max}}\) values were determined using the Eadie-Hofstee equation based on the LAT1- and LAT2-mediated AA uptakes measured for 60 s at 3.0, 10, 30, 100, 300, 1000, and 2000 \(\mu\text{M}\). The LAT1- and LAT2-mediated AA uptakes were calculated as the differences between the means of uptakes from cDNA-transfected cells and those of mock-transfected controls.

To determine \(K_i\) values, S2-LAT1, S2-LAT2, and S2-mock cells were incubated (60 s) in uptake solution with different [\(^{14}\text{C}\)]-leucine concentrations with or without inhibitor. The \(K_i\) values were determined by double-reciprocal–plot analysis where 1/[\(^{14}\text{C}\)]-leucine uptake was plotted against 1/[\(^{14}\text{C}\)]-leucine concentration. When competitive inhibition was observed, \(K_i\) values were calculated from the following equation:

\[
K_i = \text{concentration of inhibitor} / \left(\frac{\text{Leucine } K_m}{\text{with inhibitor}} - \frac{\text{Leucine } K_m}{\text{without inhibitor}}\right) - 1
\]

Statistical analyses

Values are presented as means ± S.E.M. (\(n = 6 – 8\)). Statistical differences were analyzed by Student’s unpaired \(t\)-test.

Results

Expression of hLAT1 and hLAT2 in cell lines

Exogenous hLAT1 and hLAT2 expression in S2-LAT1 and S2-LAT2 cells was examined via agarose gel electrophoresis (Fig. 2A). Consistent with levels observed in S2-mock cells, S2-LAT1 and S2-LAT2 cell lines expressed endogenous mLat1, mLat2, and m4F2hc. Furthermore, significant levels of exogenous hLAT1 and hLAT2 expression were quantitatively determined; they were performed to compare endogenous mLat1, mLat2, and m4F2hc using real-time quantitative RT-PCR from S2-LAT1 and S2-LAT2 cells, respectively (Fig. 2B). In S2-LAT1 cells, hLAT1 was detected as well as endogenous mLat1, mLat2, and m4F2hc; hLAT1 was 21-fold higher than mLat1 and >1000-fold higher than mLat2. Likewise, in S2-LAT2 cells, hLAT2 was detected as well as mock levels of endogenous mLat1, mLat2, and m4F2hc; however, hLAT2 was 86-fold higher than mLat1 and >200-fold higher than mLat2. Furthermore, hLAT1 was 2.1-fold higher than m4F2hc in S2-LAT1 cells, while hLAT2 was 8.4-fold higher than m4F2hc in S2-LAT2 cells. In S2-mock cells, hLAT1 and hLAT2 were not detected and the amount of mLat1 was 59-fold higher than that of mLat2.

Western blot analysis was performed on the membrane fractions prepared from S2-Mock cells, S2-LAT1 cells, and S2-LAT2 cells as well as T24 human bladder carcinoma cells. The antibodies raised against AA sequences of human LAT1 and LAT2, which are less conserved with mouse sequences, were used to detect exogenously expressed human LAT1 and LAT2 in S2 cells. The anti-hLAT1 antibody recognized the 125 kDa–protein band under the nonreducing condition, whereas this band shifted to the 38 kDa–protein band for hLAT1 in the S2-LAT1 cells (Fig. 2C). The size was consistent with the 38 kDa–protein band in the T24 cells (36). The antibodies raised against hLAT2 recognized the 130 kDa–protein band under the nonreducing condition, whereas this band shifted to the 45 kDa–protein band for hLAT2 in the S2-LAT2 cells (Fig. 2C).

To confirm the endogenous 4F2hc in S2 cells coupled with exogenously expressed hLAT1 and hLAT2, we conducted co-immunoprecipitation experiments in which an anti-mouse 4F2hc antibody was used to detect mouse 4F2hc-hLAT1 and mouse 4F2hc-hLAT2 complexes in S2-hLAT1 cells and S2-hLAT2 cells, respectively. The hLAT1 and hLAT2 in the immunoprecipitate were detected by antibodies raised against AA sequences of human LAT1 and LAT2, which are less conserved with mouse sequences. As shown in Fig. 2D, the anti-mouse 4F2hc antibody immunoprecipitated human LAT1 in S2-LAT1 cell membrane. A 37-kDa band was visible under reducing conditions. This band disappeared in the absorption test, confirming it as the band for hLAT1. In S2-LAT2 cells, a 45-kDa band was detected by anti-hLAT2 antibody under the reducing condition. The absorption test confirmed it as hLAT2.

Transport activity

To directly compare the transport rates of hLAT1 and hLAT2, we performed uptake studies of [\(^{14}\text{C}\)]-leucine (10 \(\mu\text{M}\)) using S2-mock, S2-LAT1, and S2-LAT2 cells. As shown in Fig. 2, S2-LAT1 and S2-LAT2 cells exhibited significantly higher l-leucine uptake than S2-mock cells (uptake by the endogenous transporter). Then we analyzed transport properties of S2-LAT1 and S2-LAT2 cells.

As presented in Fig. 3A, [\(^{14}\text{C}\)]-leucine (10 \(\mu\text{M}\)) uptake mediated by S2-LAT2 cells was time-dependent and exhibited a linear dependence during the first 2 – 3 min. The [\(^{14}\text{C}\)]-leucine uptake by S2-LAT1 cells also exhibited a similar dependence on incubation time (data not shown). Thus, all subsequent uptake measurements were conducted for 1.0 min and data expressed
as nmol/mg protein·min. The $[^{14}C]$L-leucine uptake by S2-LAT1 cells and S2-LAT2 cells was saturable and followed Michaelis-Menten kinetics (Fig. 3B for S2-LAT2 cells). The $K_m$ values were $80.3 \pm 9.7$ and $318.0 \pm 4.0 \mu M$ and the $V_{max}$ values were $16.2 \pm 2.9$ and $31.2 \pm 3.9$ ng/mg protein·min (mean $\pm$ S.E.M. of 3 measurements), respectively.

### Inhibition of $[^{14}C]$L-leucine uptake by L- and D-AAs

$[^{14}C]$L-leucine (10 $\mu M$) uptake was measured in the presence of 1.0 mM nonlabeled L- or D-AAs. As summarized in Fig. 4, A and B, $[^{14}C]$L-leucine uptake by S2-mock cells and S2-LAT1 cells was highly inhibited by the L-isomers of leucine, isoleucine, valine, phenylalanine, tyrosine, tryptophan, methionine, and histidine and a classical SL specific inhibitor, 2-aminoimicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH). L-Isomers of alanine, serine, threonine, cysteine, asparagine, and glutamine exhibited weaker but significant inhibition on $[^{14}C]$L-leucine uptake by S2-LAT1 cells (Fig. 4B), whereas weaker inhibition was detected for L-threonine and L-cysteine by S2-mock cells (Fig. 4A). Proline, glycine, cystine, basic AAs such as lysine and arginine, and acidic AAs such as glutamate and aspartate did not inhibit $[^{14}C]$L-leucine uptake by S2-mock and S2-LAT1 cells (Fig. 4: A and B); with the exception of glycine, the same general non-inhibition was observed in S2-LAT2 cells (Fig. 4C). In S2-LAT2 cells, $[^{14}C]$L-leucine uptake...
was strongly inhibited by L-isomers of AAs containing apolar and uncharged polar groups (except proline), histidine, glycine (moderate inhibition), and BCH (Fig. 4C).

D-Isomers of methionine, leucine, and phenylalanine strongly inhibited [14C]-l-leucine uptake by S2-mock and S2-LAT1 cells (Fig. 5: A and B); weak inhibition was detected with D-tyrosine in S2-mock cells. D-Isomers of isoleucine, tyrosine, histidine, cysteine, asparagine, and glutamine exhibited weaker but statistically significant inhibition of [14C]-l-leucine uptake by S2-LAT1 cells (Fig. 5B). In S2-LAT2 cells, [14C]-l-leucine uptake was weakly inhibited by D-isomers of phenylalanine, tyrosine, asparagine, methionine, leucine, isoleucine, and valine (Fig. 5C).

Inhibition of [14C]-l-leucine uptake by AA-related compounds

[14C]-l-Leucine (10 μM) uptake was measured in the presence of 1.0 mM nonlabeled AA-related compounds. As summarized in Fig. 6A, [14C]-l-leucine uptake by S2-LAT1 cells was markedly inhibited by L-dopa, 3-O-methyldopa, α-methylphenylalanine, α-methyltyrosine, α-methyldopa, and gabapentin; phenylalanine methyl-ester exhibited weak inhibition. In S2-LAT2 cells (Fig. 6B), [14C]-l-leucine uptake was strongly inhibited by L-dopa and 3-O-methyldopa, while α-methylphenylalanine, α-methyltyrosine, α-methyldopa, phenylalanine methyl-ester, and gabapentin caused weak or no inhibition.

In addition, AA-related compounds (10 μM) with bulky side chains (i.e., melphalan, T3, and T4) were also examined (Fig. 7: A and 7B). [14C]-l-Leucine uptake by S2-LAT1 cells (Fig. 7A) was markedly inhibited by T3, whereas T4 was weakly inhibitory, and melphalan was
not inhibitory. In S2-LAT2 cells (Fig. 7B), T3 and T4 were weak inhibitors of $^{14}$C$^{-}$l-leucine uptake, while melphalan was not inhibitory. Furthermore, concentration-dependent $^{14}$C$^{-}$l-leucine uptake inhibition was further probed, and the obtained $K_i$ values for BCH, T3, T4, and melphalan are summarized in Tables 3 and 4.

Discussion

Mouse cell lines S2-LAT1 and S2-LAT2 stably expressing hLAT1 and hLAT2 at high levels via hLAT1 and hLAT2 cDNA transfection have been established. The real-time quantitative RT-PCR analysis illustrated that exogenously introduced hLAT1 and hLAT2 levels were 20–1000-fold higher than endogenous mLat1 and mLat2 levels in S2-LAT1 cells and S2-LAT2 cells (Fig. 2B). In addition, hLAT1 and hLAT2 levels were 2–8-fold higher than endogenous m4F2hc. Hence, due to the high levels of hLAT1 and hLAT2 expression, one may predict that endogenous m4F2hc is associated with hLAT1 and hLAT2 in the S2-LAT1 and S2-LAT2 cells, respectively. As illustrated from the present Structure Activity Relationship (SAR) studies probing $^{14}$C$^{-}$l-leucine transport, the transport function of these stably transfected S2 cell lines reflect the properties of exogenously introduced hLAT1 and hLAT2.

In S2-mock cells, $^{14}$C$^{-}$l-leucine uptake inhibition data by L- and D-AAs (Figs. 4 and 5) are consistent with results observed using the Xenopus oocyte expression system (4, 11). The real-time quantitative RT-PCR analysis results indicate that mLat1 was expressed at higher levels than mLat2 (Fig. 2B). Furthermore, $^{14}$C$^{-}$l-
leucine uptake inhibition by L- and D-amino acids in S2-LAT1 cells are fairly consistent with results observed via hLAT1-expressing Xenopus oocytes (4, 11); L-alanine, L-serine, D-tyrosine, D-histidine, D-cysteine, D-asparagine, and D-glutamine exhibited higher levels of inhibition in S2-LAT1 cells (Fig. 4B and 5B). In S2-LAT2 cells (Fig. 4C), [14C]-leucine uptake was inhibited by neutral AAs – apolar and uncharged polar groups, except proline – and in agreement with the transport properties of LAT2 examined in hLAT2-expressing Xenopus oocytes (12, 27, 28). Also consistent with the properties of hLAT2-expressing oocytes, [14C]-leucine uptake by S2-LAT2 cells was weakly inhibited by D-asparagine and D-phenylalanine (12) (Fig. 5C). Therefore, the inhibition experiments using L- and D-AAs indicate that [14C]-leucine uptake in S2-LAT1 and S2-LAT2 cells reflect the properties of exogenously introduced hLAT1 and hLAT2, respectively.

Exogenously introduced hLAT1 and hLAT2 in S2-LAT1 and S2-LAT2 cells, respectively, are presumed to be linked with endogenous m4F2hc. The functional expression and role of 4F2hc in heterodimeric AA transporters is well established; 4F2hc promotes the trafficking of the associating transporter proteins to the plasma membrane (3, 20, 37). However, it is important to point out that 4F2hc appears to not contribute to the assembly of transporter substrate binding sites; a fusion protein of LAT1 and 4F2hc and that of LAT1 and the other single membrane spanning heavy chain rBAT (related to b6+ AA transporter) have exhibited similar substrate selectivity and affinity (20). Furthermore, hLAT1 and human 4F2hc coexpression and hLAT1 and mouse 4F2hc coexpression in Xenopus oocytes resulted in similar substrate selectivity and affinity (data not shown). Hence, L-leucine transport detected in the absence of Na+ in S2-LAT1 and S2-LAT2 cells reflects the inherent properties of hLAT1 and hLAT2; cells that may mimic transport mediated by hLAT1 and hLAT2 in vivo and affords novel in vitro screening tools.

Using S2-LAT1 and S2-LAT2 cells, we have examined the SAR of hLAT1 and hLAT2 expressed in mammalian cells. As illustrated in Fig. 6, A and B, N-methylphenylalanine had little effect on [14C]-leucine uptake in both S2-LAT1 and S2-LAT2 cells, which is consistent with previous data from inhibition studies on rLAt1-expressing oocytes (38). Thus, the α-amino group appears essential for substrate-binding by hLAT1 and hLAT2. In agreement, tyramine and dopamine, which both lack α-carboxyl groups, and carbipoda, an N-amino derivative of L-α-methylldopa (Fig. 1), failed to inhibit [14C]-leucine uptake in S2-LAT1 and S2-LAT2 cells (Fig. 6: A and B). These results are in contrast to the system T transporter TAT1 that recognizes aromatic AA substrates as anions (39). All compounds that efficiently inhibited [14C]-leucine uptake in S2-LAT1 and S2-LAT2 cells were α-AAs, except gabapentin (a γ-AA), and inhibited hLAT1-mediated [14C]-leucine uptake but not hLAT2-mediated uptake (Fig. 6: A and B).

It is interesting that hLAT1 accepts α-methyl AA while hLAT2 does not (Fig. 6: A and B). L-α-Methylphenylalanine, L-α-methyltyrosine, and L-α-methylldopa inhibited hLAT1-mediated [14C]-leucine uptake but not hLAT2-mediated uptake, which indicates that the binding site of hLAT1, but not hLAT2, can accommodate methyl substituents on the α-carbon. Therefore, the substrate binding site on hLAT1 seems to have more space around the α-carbon–binding region compared to

---

**Table 3.** Kinetic parameters of amino acid–related compounds in S2-LAT1 cells

<table>
<thead>
<tr>
<th>Compounds</th>
<th>$K_i$ ($\mu$M)</th>
<th>$K_m$ ($\mu$M)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leucine</td>
<td>114.0 ± 8.3</td>
<td>80.3 ± 9.7</td>
</tr>
<tr>
<td>BCH</td>
<td>132.0 ± 27.8</td>
<td></td>
</tr>
<tr>
<td>Melphalan</td>
<td>205.0 ± 32.0</td>
<td></td>
</tr>
<tr>
<td>T3</td>
<td>1.7 ± 0.1</td>
<td></td>
</tr>
<tr>
<td>T4</td>
<td>115.0 ± 2.0</td>
<td></td>
</tr>
</tbody>
</table>

**Table 4.** Kinetic parameters of amino acid-related compounds in S2-LAT2 cells

<table>
<thead>
<tr>
<th>Compounds</th>
<th>$K_i$ ($\mu$M)</th>
<th>$K_m$ ($\mu$M)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leucine</td>
<td>480.0 ± 19.4</td>
<td>318.0 ± 4.0</td>
</tr>
<tr>
<td>BCH</td>
<td>315.0 ± 68.6</td>
<td></td>
</tr>
</tbody>
</table>

---

Fig. 7. [14C]-Leucine uptake inhibition by amino acids and related compounds. [14C]-Leucine (1.0 $\mu$M) was measured in the absence (–) or presence of 10 $\mu$M non-radioabeled triiodothyronine (T3), thyroxine (T4), and melphalan for S2-LAT1 (A) and S2-LAT2 cells (B). The uptake values are expressed as percent of the [14C]-leucine uptake control measured in the absence of inhibitors (–). **$p<0.05$, ***$p<0.01$ vs control.
hLAT2. Also consistent with a more rigid hLAT2 binding site, hLAT1 accepts gabapentin while hLAT2 does not (Fig. 6: A and B); this situation enables hLAT2 to exclude α-methyl AA and the ω-AA gabapentin.

Consistent with the observations on SL in cultured cells or membrane-vesicle preparations, hLAT1-mediated transport is inhibited by thyroid hormones (i.e., T3 and T4) and by melphalan (Fig. 7A) (6 – 8, 40, 41). It was previously reported that IU12/ASUR4, a Xenopus homolog of LAT1, accepts thyroid hormones as substrates (42); based on the double-reciprocal-plot analysis (data not shown), these modified AAs with bulky side chains are determined to be competitive inhibitors of hLAT1-mediated transport. Therefore, hLAT1’s binding site may accommodate bulky side chains such as those of the thyroid hormones and melphalan. In contrast, hLAT2-mediated transport is inhibited markedly by thyroid hormones and melphalan (Fig. 7B). Consequently, hLAT1’s substrate binding site appears to contain a larger pocket (and/or more flexible pocket) that may accept the bulky side chains of thyroid hormones and melphalan. On the other hand, hLAT2 compared to hLAT1, exhibits a broader substrate selectivity for common neutral AAs.

In the present study, we have established mouse cell lines stably expressing human SL transporters hLAT1 and hLAT2 and demonstrate that these cell lines are quite useful for evaluating the interaction of chemical compounds or LAT1 and hLAT2. SL is a major route through which living cells take up neutral AAs from extracellular fluids (1). It was shown that LAT1 is upregulated in tumor cells to provide tumor cells with nutrients to support their continuous growth and proliferation (1, 3, 4, 21, 22). In addition, LAT1 is proposed to mediate the permeation of AAs through blood-tissue barriers such as the BBB and PB (23 – 26). In contrast, LAT2 may be regarded as the “normal cell type” transporter essential for AA transport in cells and important in epithelial transport of AAs in the small intestine and kidney (3, 12, 28). Therefore, the development of isoform specific inhibitors or substrates should have important therapeutic implications (3). For example, LAT1-selective inhibitors may be useful as anti-tumor agents with less side effects on non-tumor cells; selectively inhibiting LAT1 predominantly expressed in tumor cells may sufficiently suppress tumor cell growth by reducing the AA supply to tumor cells (3, 43, 44) – an “AA starve-out strategy”. Although it is not LAT1-specific, a new class of immunosuppressant, brasicardin A (BraA), has been found to be an inhibitor of the AA transporter SL (45). Usui et al. suggested that the immunosuppressive activity of BraA is induced by AA deprivation via the inhibition of SL and that the AA transporter is a target for the immunosuppressant (45).

Another application of LAT1-selective compounds may be for diagnostic usage; such compounds can be specifically designed to target cancer cells via LAT1 interactions at blood–tissue barriers (3). Anti-tumor agents designed to be transported by LAT1 are expected to be selectively taken up and accumulate in tumor cells. Recently, Kaira et al. evaluated the diagnostic usefulness of L-[3-18F]-α-methyltyrosine ([18F]FMT), an AA tracer for positron emission tomography (PET), in non-small-cell lung cancer (NSCLC) patients (46). In that study, they compared [18F]FMT to 2-[18F]-fluoro-2-deoxy-D-glucose ([18F]FDG) tumor uptake and correlated the results with LAT1 expression. They found that [18F]FMT PET had no false-positives in primary tumor and lymph node metastasis detection and could improve NSCLC diagnostic performance. In addition, [18F]FMT uptake correlated with LAT1 expression and showed a significant association with cellular proliferation (45). Therefore, by having more robust in vitro tools for high-throughput compound screening, S2-LAT1 and S2-LAT2 cell lines established in the present study are expected to contribute to the development of novel anti-cancer and diagnostic agents.

Acknowledgments

This work was supported in part by grants from the Ministry of Education, Culture, Sports, Science, and Technology of Japan; the Japan Society for the Promotion of Science; the Promotion and Mutual Aid Corporation for Private Schools of Japan; Japan Foundation for Applied Enzymology; and the Japan Health Sciences Foundation. The authors are grateful to Michi Takahashi for technical assistance.

References

1 Christensen HN. Role of amino acid transport and counter-transport in nutrition and metabolism. Physiol Rev. 1990;70:43–77.
6 Goldenberg GJ, Lam HY, Begleiter A. Active carrier-mediated


10 Patel NJ, Fullone JS, Anders MW. Brain uptake of S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-L-cysteine, the glutathione and cysteine S-conjugates of the neurotoxin dichloroacetylene. Brain Res Mol Brain Res. 1993;17:53–58.


